Nanoparticles in targeted cancer therapy: Mesoporous silica nanoparticles entering preclinical development stage

Nanomedicine

Volumn 7, Issue 1, 2012, Pages 111-120

  Rosenholm, Jessica M ^a   Mamaeva, Veronika ^b   Sahlgren, Cecilia ^a,b   Lindén, Mika ^c  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

biodegradation; biodistribution; cancer; in vivo; mesoporous silica nanoparticles; preclinical testing; safety; therapeutic efficacy

Indexed keywords

DOXORUBICIN; NANOPARTICLE; SILICON DIOXIDE;

BIODEGRADATION; BIOMEDICINE; CANCER THERAPY; CLEARANCE; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; POROSITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICITY TESTING; TREATMENT OUTCOME;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; METABOLIC CLEARANCE RATE; MICE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; PARTICLE SIZE; POROSITY; SAFETY; SILICON DIOXIDE; SURFACE PROPERTIES; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84555202674     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.166     Document Type: Review

References (58)

1. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
2. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
3. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab. 10, 836-841 (2009).
4. Gordon EM, Lopez FF, Cornelio GH et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int. J. Oncol. 29, 1053-1064 (2006).
5. Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16, 6139-6149 (2010).
6. Wesselinova D. Current major cancer targets for nanoparticle systems. Curr. Cancer Drug Targets 11, 164-183 (2011).
7. Zhang L, Gu FX, Chan JM et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008). (Pubitemid 351556021)
8. Ali I, Rahis-Uddin, Salim K et al. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11, 135-146 (2011).
9. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
10. Ow H, Larson D, Srivastava M et al. Bright and stable core-shell fuorescent silica nanoparticles. Nano Lett. 5, 113-117 (2005). (Pubitemid 40168913)
11. Benezra M, Penate-Medina O, Zanzonico PB et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121(7), 2768-2780 (2011).
12. Tilocca A. Models of structure, dynamics and reactivity of bioglasses: a review. J. Mater. Chem. 20, 6848-6858 (2010).
13. Unger KK, Rupprecht H, Valentin B et al. The use of porous and surface modifed silicas as drug delivery and stabilizing agents. Drug Development Ind. Pharm. 9, 69-91 (1983). (Pubitemid 13149439)
14. Simovic S, Ghouchu-Eskandar N, Sinn AM et al. Silica materials in drug delivery applications. Curr. Drug Deliv. Technol. 8(3), 269-276 (2011).
15. Manzano M, Colilla M, Vallet-Regi M. Drug delivery from ordered mesoporous matrices. Expert Opin. Drug Del. 6, 1383-1400 (2009).
16. Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles- opportunities and challenges. Nanoscale 2, 1870-1883 (2010).
17. He QJ, Shi JL. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 21, 5845-5855 (2011)
18. Vivero-Escoto JL, Slowing II, Trewyn BG et al. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6, 1952-1967 (2010).
19. Santos, HA; Salonen, J; Bimbo, LM et al. Mesoporous materials as controlled drug delivery formulations. J. Drug Delivery Sci. Tech. 21, 139-155 (2011).
20. Mellaerts R, Mols R, Jammaer JAG et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm. 69, 223-230 (2008).
21. Vallet-Regi M, Balas F, Colilla M et al. Bone-regenerative bioceramic implants with drug and protein controlled delivery capability. Progr. Solid State Chem. 36, 163-191 (2008).
22. Dai C, Yuan Y, Liu C et al. Degradable, antibacterial silver exchanged mesoporous silica spheres for hemorrhage control. Biomaterials 30, 5364-5374 (2009).
23. López T, Basaldella EI, Ojeda MJ et al. Encapsulation of valproic acid and sodic phenytoin in ordered mesoporous SiO solids for the treatment of temporal lope epilepsy. Optical Mater. 29, 75-81 (2006). (Pubitemid 44389906)
24. Wu SH, Lin YS, Hung Y et al. Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. Chem. Bio. Chem. 9, 53-57 (2008).
25. Lin YS, Wu SH, Hung Y et al. Multifunctional composite nanoparticles: magnetic, luminescent, and mesoporous. Chem. Mater. 18, 5170-5172 (2006). (Pubitemid 44759376)
26. Liu HM, Wu SH, Lu CW et al. Mesoporous silica nanoparticles improve magnetic labeling effciency in human stem cells. Small 4, 619-626 (2008).
27. Lu CW, Hung Y, Hsiao JK et al. Bifunctional magnetic silica nanoparticles for highly effcient human stem cell labeling. Nano Lett. 7, 149 (2007).
28. Hsiao JK, Tsai CP, Chung TH et al. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small 4, 1445-1452, (2008).
29. Steinbacher JL, Lathrop SA, Cheng K et al. Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. Small 6, 2678-2682 (2010).
30. Taylor KM, Kim JS, Reiter WJ et al Mesoporous silica nanospheres as highly effcient MRI contrast agents. J. Am. Chem. Soc. 130, 2154-2155 (2008). (Pubitemid 351287981)
31. Lee CH, Cheng SH, Wang YJ et al. Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution. Adv. Funct. Mater. 19, 215-222 (2009).
32. He Q, Zhang Z, Gao F et al. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 7, 271-280 (2011).
33. Huang X, Li L, Liu T et al. The shape effect of Mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 5(7), 5390-5399 (2011).
34. Kim J, Kim HS, Lee N et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fuorescence imaging and for drug delivery Angew. Chem. Int. Ed. 47, 8438-8441 (2008).
35. Lee JE, Lee N, Kim H et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fuorescence imaging, and drug delivery. J. Am. Chem. Soc. 132, 552-557 (2010).
36. Lu J, Liong M, Li Z et al. Biocompatibility, biodistribution, and drug-delivery effciency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6, 1794-1805 (2010).
37. Meng H, Xue M, Xia T et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5, 4131-4144 (2011).
38. Mamaeva V, Rosenholm JM, Bate-Eya LT et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther. 19, 1538-1546 (2011).
39. Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression effcacy of mesoporous silica nanoparticles-based drug delivery system: enhanced effcacy by folate modifcation. Nanomed. Nanotech. Biol. Med. doi:10.1016/j. nano.2011.06.002 (2011) (Epub ahead of print).
40. Etienne M, Walcarius A. Analytical investigation of the chemical reactivity and stability of aminopropyl-grafted silica in aqueous medium. Talanta 59, 1173-1188 (2003).
41. Cauda V, Schlossbauer A, Bein T. Bio-degradation study of colloidal mesoporous silica nanoparticles: effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microporous Mesoporous Mater. 132, 60-71 (2010).
42. Mortera R, Fiorilli S, Garrone E et al. Pore occlusion in MCM-41 spheres immersed in SBF and the effect on ibuprofen delivery kinetics: a quantitative model. Chem. Eng. J. 156, 184-192 (2010).
43. Martin KR. The chemistry of silica and its potential health benefts. J. Nutr. Health Aging 11, 94-97 (2007).
44. Souris JS, Lee CH, Cheng SH et al. Surface charge-mediated rapid hepatobiliary exretion of mesoporous silica nanoparticles. Biomaterials 31, 5564-5574 (2010).
45. Hillegass JM, Blumen SR, Cheng K et al. Increased effcacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int. J. Cancer. 129, 233-244 (2011).
46. Wang T, Chai F, Q. Fu et al. Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy, J. Mater. Chem. 21, 5299-5306 (2011).
47. Huang IP, Sun SP, Cheng SH et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein- mediated drug resistance. Mol. Cancer Ther. 10, 761-769 (2011).
48. Lee S, Yun H-S, Kim S-H. The comparative effects of mesoporous silica nanoparticles and colloidal silica on infammation and apoptosis. Biomaterials 32(35), 9434-9443 (2011).
49. Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. Chem. Mater. 21, 3979-3986 (2009).
50. Slowing II, Wu CW, Vivero-Escoto JL et al. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small 5, 57-62 (2009).
51. Zhao Y, Sun X, Zhang G et al. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 5, 1366-1375 (2011).
52. Hudson SP, Padera RF, Langer R et al. The biocompatibility of mesoporous silicates. Biomaterials 29, 4045-4055 (2008).
53. Huang X, Zhuang J, Teng X et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 31, 6142-6153 (2010).
54. Liu T, Li L, Teng X et al. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials 32, 1657-1668 (2011).
55. Tao Z, Morrow MP, Asefa T et al. Mesoporous silica nanoparticles inhibit cellular respiration. Nano Lett. 8, 1517-1526 (2008).
56. Al Shamsi M, Al Samri MT, Al-Salam S et al. Biocompatibility of calcined mesoporous silica particles with cellular bioenergetics in murine tissues. Chem. Res. Toxicol. 23, 1796-1805 (2010).
57. Huang X, Zhuang J, Teng X et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species Biomaterials 31, 6142-6153 (2010).
58. Luo T, Huang P, Gao G et al. Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode X-ray and NIR fuorescence imaging. Optics Express 19, 17030-17039 (2011).